No Data
No Data
C HEALTH GP: ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2024
C HEALTH GP (08225) released its annual performance, with a loss attributable to Shareholders of 14.519 million yuan, a year-on-year decrease of 74.97%.
C HEALTH GP (08225) released its annual performance report for the year ending December 31, 2024, and the group achieved operating...
C HEALTH GP: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2024
All the way up! The Innovative Drugs Sector in Hong Kong stocks surged collectively, with multiple stocks doubling this year. Who is reshaping the valuation?
The rise in the Hong Kong stock market's Innovative Drugs Sector continues. Market analysts point out that this wave of Innovative Drugs momentum benefits from a combination of factors including market sentiment, policy, and the realization of the companies' own commercial value.
What does AI pharmaceuticals still lack before a market explosion? | Focus
① From the discovery of targets to the identification of preclinical candidate compounds, current generative AI mainly focuses on the early stages of drug development, which can lead to significant acceleration; ② If AI in drug development is to further expand the realm of possibilities, it must explore more profitable real-world applications.
C HEALTH GP (08225): Wang Dajun resigned as a non-executive Director.
C HEALTH GP (08225) announced that due to the adjustment of the group's organizational structure and Mr. Wang Dajun's personal...